Discussion about this post

User's avatar
Jay Roshe's avatar

Your point about endpoints for clinical trials is spot-on. It'll be interesting to see what ARPA-H PROSPR develops over the next five years in its goal of running trials with FDA using surrogate aging biomarkers.

Chris Davison's avatar

reproducibility and predictive functionality are the keys

No posts

Ready for more?